Alteplase Before Thrombectomy Loses Value After 170 Minutes

Temporal Dynamics in Large Vessel Occlusion Revascularization

Mechanical thrombectomy is the established standard of care for patients presenting with acute ischemic stroke due to large-vessel occlusion in the anterior circulation [1, 2]. While clinical guidelines generally support bridging therapy, which involves the administration of a clot-dissolving agent like intravenous alteplase prior to the endovascular procedure, the added value of this approach for patients admitted directly to thrombectomy-capable centers remains a point of contention [3, 4, 5]. A meta-analysis of 2,143 patients found no significant difference in functional independence, defined as a modified Rankin Scale score of 0 to 2 at 90 days, between direct mechanical thrombectomy and bridging therapy, reporting a pooled odds ratio of 0.96 (95% CI, 0.79 to 1.17; p = 0.39) [6, 7]. Conversely, a larger systematic review of 36,123 patients suggested that bridging therapy was associated with a 21 percent higher likelihood of favorable functional outcomes (RR 1.21, 95% CI 1.13 to 1.29) and lower mortality (RR 0.75, 95% CI 0.68 to 0.82) [5]. These discrepancies often stem from variations in treatment delays and the status of the penumbra, the region of ischemic but still salvageable brain tissue surrounding the irreversible infarct core. A new analysis of international trial data now clarifies how the interval from symptom onset to treatment dictates the clinical and economic viability of bridging therapy.

Modeling Long-Term Outcomes Across 16 Nations

To evaluate the economic and clinical viability of bridging therapy, researchers conducted a comprehensive analysis of 2,268 patients with a median age of 71 years, 44% of whom were female. These individuals were drawn from six clinical trials focusing on anterior circulation large-vessel occlusion, specifically those eligible for both intravenous thrombolysis and mechanical thrombectomy. The study utilized 90-day functional outcome distributions from this patient population to populate a hypothetical cohort of 10,000 patients, modeling their health trajectories over a 15-year horizon. This long-term projection allowed the authors to assess the sustained impact of treatment decisions beyond the immediate post-stroke period, which is essential for understanding the lifetime costs of disability management. The researchers employed a decision tree integrated with a Markov model (a mathematical framework used to simulate the progression of patients through different health states over time) to estimate costs and quality-adjusted life years (QALYs). QALYs serve as a measure of disease burden that accounts for both the quality and the quantity of life lived, where one QALY represents one year of perfect health. To determine the economic advantage of one intervention over another, the team calculated the incremental net monetary benefit (INMB), a metric that represents the value of health gains after accounting for the costs of the intervention. This analysis was applied across 16 different countries, using a willingness-to-pay threshold of one gross domestic product per capita for each nation to define cost-effectiveness in a local context. The robustness of these findings was verified through one-way sensitivity and probabilistic sensitivity analyses, which are statistical methods used to test how variations in input parameters, such as drug costs or complication rates, affect the overall results. By comparing intravenous alteplase plus thrombectomy versus thrombectomy alone in patients admitted directly to thrombectomy-capable centers, the study sought to identify the precise temporal window where the addition of thrombolysis remains beneficial. The integration of individual patient data with these rigorous economic models provided a granular view of how onset-to-treatment time dictates the value of bridging therapy on a global scale.

The 170-Minute Threshold for Clinical Utility

When the researchers analyzed the data without accounting for the specific time from symptom onset to treatment, bridging therapy appeared to be a viable economic option in 13 of the 16 countries studied. In these nations, the incremental net monetary benefit (INMB) ranged from $85 to $3,618, with a 50% to 65% probability that the intervention was cost-effective. However, this aggregate view obscured significant regional differences; bridging therapy was not cost-effective in the United States, China, and Vietnam when time was not factored into the model. Furthermore, the overall health gains across the cohort were modest, with improvements ranging from only 0.06 to 0.08 quality-adjusted life years (QALYs) per patient. The clinical utility of intravenous alteplase became much clearer when the authors stratified the data into specific onset-to-intravenous thrombolysis time intervals: less than 140 minutes, 140 to 169 minutes, 170 to 199 minutes, and 200 minutes or more. For patients treated within the earliest window of less than 140 minutes, bridging therapy was cost-effective in all 16 countries, demonstrating an INMB between $615 and $30,645 and a high probability of cost-effectiveness ranging from 82% to 98%. This economic benefit persisted, albeit with less certainty, in the 140 to 169 minute window. In this second interval, the intervention remained cost-effective across all 16 countries, though the INMB narrowed to $86 to $16,918 and the probability of cost-effectiveness decreased to between 51% and 77%. A critical shift in value occurred as the time from stroke onset increased. Once the onset-to-intravenous thrombolysis time reached the 170 to 199 minute range, intravenous alteplase plus thrombectomy was no longer cost-effective in 8 of the 16 countries. This suggests that the added benefit of thrombolysis diminishes rapidly as the three-hour mark approaches. For any treatment initiated at or beyond 200 minutes, the incremental net monetary benefit became universally negative, indicating that the costs and potential risks of adding alteplase outweigh the marginal functional gains for patients admitted directly to thrombectomy-capable centers.

Diminishing Returns and Late-Window Risks

The study findings highlight a clear temporal boundary for the utility of bridging therapy in patients admitted directly to centers capable of endovascular treatment. For onset-to-intravenous thrombolysis times exceeding 200 minutes, the incremental net monetary benefit was negative in all 16 countries included in the analysis. The incremental net monetary benefit is a statistical measure that converts health gains into a dollar value and subtracts the additional costs of treatment; a negative result indicates that the intervention's costs and risks outweigh its clinical benefits. For clinicians, this suggests that the marginal functional gains achieved by adding alteplase to mechanical thrombectomy in late-presenting patients do not justify the associated expenditures or the potential for complications. The researchers concluded that the cost-effectiveness of bridging therapy diminishes progressively with longer onset-to-treatment times and becomes detrimental after 200 minutes. This progressive decline reflects the narrowing window in which thrombolysis can effectively salvage tissue before the risks of the procedure, such as symptomatic intracranial hemorrhage (a serious complication where bleeding occurs within the brain following reperfusion), begin to eclipse the benefits. Because the economic and clinical value of the intervention is so closely tied to the clock, these results suggest that for patients arriving at thrombectomy-capable centers near the 200-minute mark, the most efficient and beneficial course of action may be to proceed directly to mechanical revascularization rather than initiating intravenous thrombolysis. This approach may optimize resource utilization while avoiding the risks of thrombolytic therapy in a population where the likelihood of benefit is minimal.

References

1. Berkhemer OA, Fransen P, Beumer D, et al. A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke. New England Journal of Medicine. 2014. doi:10.1056/nejmoa1411587

2. Saver JL, Goyal M, Bonafé A, et al. Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke. New England Journal of Medicine. 2015. doi:10.1056/nejmoa1415061

3. Elfil M, Ghaith H, Aladawi M, Morsi R, Al-Mufti F. Abstract TP142: Intravenous Thrombolysis In Combination With Mechanical Thrombectomy: An Updated Meta-Analysis Of Clinical Trials. Stroke. 2023. doi:10.1161/str.54.suppl_1.tp142

4. LeCouffe NE, Kappelhof M, Treurniet KM, et al. A Randomized Trial of Intravenous Alteplase before Endovascular Treatment for Stroke. New England Journal of Medicine. 2021. doi:10.1056/nejmoa2107727

5. Ghaith HS, Elfil M, Gabra MD, et al. Intravenous thrombolysis before mechanical thrombectomy for acute ischemic stroke due to large vessel occlusion; should we cross that bridge? A systematic review and meta-analysis of 36,123 patients.. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2022. doi:10.1007/s10072-022-06283-6

6. Li H, Yang S, Zhong Y, et al. Mechanical Thrombectomy with or without Intravenous Thrombolysis in Acute Ischemic Stroke: A Meta-Analysis for Randomized Controlled Trials. European Neurology. 2021. doi:10.1159/000520085

7. Lin C, Saver JL, Ovbiagele B, Huang W, Lee M. Endovascular thrombectomy without versus with intravenous thrombolysis in acute ischemic stroke: a non-inferiority meta-analysis of randomized clinical trials. Journal of NeuroInterventional Surgery. 2021. doi:10.1136/neurintsurg-2021-017667